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Neoangiogenesis and expression of the main angiogenic factor Vascular endothelial growth
factor (VEGF) are critical steps already present at an early stage of breast cancer develop-
ment. As tumor growth progresses other pro-angiogenic factors, including bFGF, TGFa
and IL-8, are overexpressed and act in addition to VEGF. VEGF expression has been associ-
ated to poor prognosis and therapy outcome in breast cancer. Moreover, several studies
have documented that HER-2 overexpression induces VEGF expression/secretion and neo-
vascularization and that VEGF expression increases when tumors become resistant to
treatment. On these bases the anti-VEGF drug Bevacizumab has been evaluated in the clin-
ical setting in breast cancer patients. Recently, phase III studies have demonstrated that
Bevacizumab in combination with taxanes produces a high rate of responses and increases
the Progression Free survival of breast cancer patients. A large array of studies is currently
ongoing with Bevacizumab in combination with chemotherapy and hormone-therapy in
the metastatic, neoadjuvant and adjuvant setting.
 2008 Elsevier Ltd. All rights reserved.1. Angiogenesis and breast cancer Now it is increasingly clear that the cancer cell is only par-Breast cancer is themost common type, accounting for 26% of
all female cancers in the United States. In 2007, approxi-
mately 178,480 women and 2030 men will be diagnosed with
invasive breast cancer and 40,460 women and 480 men will
die from the disease.
Recently, our understanding of breast cancer biology is
increasing by the findings that the breast cancer represents
a family of tumours, sharing the same origin organ, with spe-
cific molecular features and prognostic implications. In this
regard, molecular markers as hormonal receptors (HRs) and
HER2/neu are the most important tools for therapeutic deci-
sion, albeit genomic profiling, performed with tissue chip
microarrays, are a very interesting and promising approach.
During the last three decades, since Judah Folkman
hypothesis in early 1970s,1 accumulating data concerning tu-
mour biology suggest that angiogenesis is a crucial step in the
growth, invasion and metastatic dissemination in cancer.er Ltd. All rights reserved
; fax: +39 081 2203147.
ora).tially responsible for tumour progression and that the tumour
microenvironment, formed by endothelial and bone marrow
derived cells, has a crucial role in disease development.
Therefore, acting on these cells can augment the efficacy of
cancer cell targeted therapy as chemotherapeutic agents
and molecular targeted drugs.
The angiogenesis is an important developmental mecha-
nism implicated in many physiological and pathological pro-
cesses. Amongst the many factors implicated in angiogenesis
most attention is catalysed, during these years, by VEGF (vas-
cular endothelial growth factor) system.
VEGF-A (commonly referred as VEGF), the major proangio-
genic factor, circulating as various isoforms (VEGF121 and
VEGF165), belong to the VEGF family of growth factors, com-
prising VEGF-A (referred as VEGF), VEGF-B, VEGF-C, VEGF-D
VEGF-E and PlGF.2,3
VEGF production is finely regulated by various stimuli as
hypoxia (via hypoxia-inducible factor 1a, HIF-1a),4 oncogenes.
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receptors (EGFR and HER2).5
VEGF activity is mediated by binding on cell surface ex-
pressed tyrosine-kinase receptors, called VEGFR-1 (flt-1), VEG-
FR-2 (flk-1/KDR) and VEGFR-3 (flt-4) and Neuropilin1–2.6
Although VEGFR-2 is classically defined as the principal
mediator of VEGF transduction activity, increasing evidence
suggests a central role in many processes also for VEGFR-1.
VEGF promotes the growth of structurally chaotic and
functional aberrant vessels into tumour burden,7 increases
permeability, raising intratumoural pressure that, in turn,
prevents the penetration of chemotherapeutic agents into
the tumour,8 and prevents the apoptosis of immature pericyte
on vessels critical for the tumour.9
All these features, added to the limited role that VEGF
plays in healthy adults, explain why its targeting is strongly
pursued for therapeutic purposes.
The importance of VEGF in breast cancer was first proved
in preclinical and in clinical setting.
In the preclinical models VEGF expressing breast cancer
cells demonstrated increased growth and metastatic poten-
tial in human tumour xenografts.10 In the clinical setting
VEGF overexpression in the early stage breast cancer was re-
lated to worse distant Disease-free survival, accounting for a
major metastatic potential, and with the resistance to sys-
temic chemotherapy and hormonal therapy.11–14 Moreover,
HER2 overexpression in breast cancer is associated with VEGF
overexpression.15–17
Recent preclinical studies show that VEGFR-2 is overex-
pressed on some breast cancer cells and that VEGF can act
as an autocrine loop on this tumour cells, associated with a
paracrine loop involving cancer and endothelial cells. This
observation, albeit very interesting, has not been yet
confirmed in clinical setting, though many reports show the
presence of either VEGFR1 and/or -2 on breast cancer cell
surface.18,19
The first VEGF antagonist was a monoclonal antibody ap-
proved by FDA for the treatment of metastatic colorectal pa-
tients in February 2004 and, after few months, worldwide
with the same indication: bevacizumab (Avastin).
Parallel to colorectal cancer, bevacizumab demonstrated
activity in many type of cancer such as renal cell cancer
(RCC), non-small cell lung cancer (NSCLC) and breast cancer.
In this regard, bevacizumab was approved by EMEA on the
27th March 2007 for the treatment of previously untreated
metastatic breast cancer patients.
Bevacizumab is a humanised (93% human and 7% murine)
monoclonal antibody designed to efficiently recognise and
bind all the major isoforms of circulating VEGF. With a termi-
nal half-life of 17–21 d it can be associated with the most
common chemotherapeutic administration schedules.20
2. Preclinical data with bevacizumab
In human breast cancer xenograft models either the A4.6.1,
the murine precursor of bevacizumab or bevacizumab has
demonstrated a certain activity in inhibiting angiogenesis
and tumour growth and spreading, given alone or in combi-
nation with chemotherapeutics and other targeted agents
(trastuzumab).21–233. Clinical data with bevacizumab: focus on
mBC
On the basis of preclinical data some early clinical studies
were conducted in humans to assess the feasibility of bev-
acizumab administration. Following phase I studies some
phase I/II studies were performed in breast cancer patients
to define the optimal dose and obtain an early assessment
of the drug activity in this setting.
Cobleigh and colleague conducted a phase I/II trial in 75
pretreated mBC patients to primarily assess the overall re-
sponse rate and the safety of three different doses of bev-
acizumab (3, 10, 20 mg/kg every 2 weeks) administered
alone. At the dose of 10 mg/kg, there was one CR and four
PR versus zero and one, respectively, for the 20 mg/kg dose.
Although the overall response rate (ORR) was very low, this
study showed a median duration of response of 5.6 months
and provided better data for the antiangiogenic drug alone
than was observed in the early phase II studies with capecit-
abine.24 The safety profile was favourable with hypertension
G3 in 17% of patients treated with the intermediate dose com-
paring with 22% and 19% of patients treated with 3 mg/kg and
20 mg/kg, respectively. Based on these data 10 mg/kg every 2
weeks or 15 mg/kg every 3 weeks was selected as the dose
for the further phases II and III studies.
These data support the investigation of bevacizumab com-
bined with chemotherapy. The first phase III study was de-
signed and performed. In this study, 462 pretreated mBC
patients were randomised to receive capecitabine plus bev-
acizumab or capecitabine alone. The progression free survival
(PFS) was the primary end-point and there was no statistically
significant difference between the two groups of patients (4.2
versus 4.9 for those treated with capecitabine + bev-
acizumab). Similarly, also median overall survival (OS), 14.5
versus 15.1 for capecitabine versus capecitabine + bev-
acizumab, respectively, was not reached a statistical differ-
ence. The ORR (assessed by an independent review facility)
was higher for the combination treatment arm: 19.8 months
versus 9.1 months (p 0.001).25 The key explanation of the fail-
ure to achieve PFS and OS advantages for this study was that
VEGF is expressed throughout the tumour lifecycle, but other
factors (i.e. bFGF, TGF-b, PlGF and pleiotrophin) come into play
at later stages. Thus tumours may escape anti-VEGF treat-
ment by using alternative pro-angiogenic pathways. A direct
consequence of this theory is that VEGF-driven angiogenesis
plays a more important role in early stage of tumour forma-
tion, thus the anti-VEGF treatments should be administrated
early in cancer therapy.
A more recent phase III trial evaluated weekly paclitaxel
alone or in combination with bevacizumab, given at the dose
of 10 mg/kg every 2 weeks, as first-line treatment in locally
advanced mBC patients. The trial was early stopped due a
scheduled interim analysis by an independent data monitor-
ing committee which concluded that was met the PFS, pri-
mary end-point of the study. Indeed at the date of the
interim analysis PFS was 5.8 months for patients who re-
ceived paclitaxel alone and 11.4 months for those who re-
ceived combination therapy (p < 0.0001). In addition, the ORR
was increased from 23.4% for paclitaxel arm to 48% for com-
bination arm (p < 0.0001). This meaningful increase in PFS and
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Although the increased trend for OS observed for patients
who received combination therapy was not significantly dif-
ferent compared to those receiving paclitaxel alone (26.6 ver-
sus 24.8, respectively; p 0.14), an exploratory analysis reported
that the addition of bevacizumab to paclitaxel led to higher 1
year OS (82.3 versus 72.8%, p 0.007).26
To explain the lack in survival advantage it may be argued
that in the study analysis were not considered the different
subsequent therapies that may affect the results of first-line
therapy.
However, the magnitude of the PFS and ORR data, higher
than other ever observed in first-line mBC treatment, led to
EMEA and FDA approval of the combination of bevacizumab
with paclitaxel in first-line mBC patients.
Other studies assessing efficacy and feasibility of the com-
bination of bevacizumabwith other targeted and conventional
agents were performed in these years or are ongoing.27–31
In particular the combination of bevacizumab and doce-
taxel, another drug widely used in mBC treatment, was inves-
tigated by some phase II and III studies with some
successes.27,28 A phase III study, known as AVADO, random-
ised 736 patients until March 2007 to receive docetaxel plus
placebo or bevacizumab every 3 weeks at the dose of
7.5 mg/kg or 15 mg/kg in combination with docetaxel. The
AVADO trial demonstrated a higher ORR, Time to Treatment
Failure and PFS in the bevacizumab 7.5 mg/kg and 15 mg/kg
as compared to placebo arm.
Other ongoing two phase III studies, RIBBON1 and 2 are
evaluating the role of bevacizumab combination with some
chemotherapy regimens. In particular, RIBBON1 study will
evaluate the safety and the efficacy of the bevacizumab com-
bined with anthracycline-based, capecitabine and taxane as
first-line therapy for mBC patients. The RIBBON2 study is de-
signed to assess the efficacy of bevacizumab when associated
with standard non-anthracycline-based chemotherapy in
previously treated mBC patients.
After the approval by major regulatory agencies (i.e. FDA
and EMEA) of the first-line combination of bevacizumab and
paclitaxel, a large phase IV started assessing the safety profile
of this treatment in locally recurrent mBC patients (MO19391).
Based on the abovementioned evidence of HER2 and VEGF
co-expression on breast cancer cell surface and the crosstalk
between HER2 pathway and VEGF,23 a phase I/II study was
performed with bevacizumab associated to trastuzumab in
HER2 positive mBC patients. Early results on 37 patients sug-
gest that the combination is well tolerated with only few G3/
G4 events reported. Preliminary efficacy data showed 19 PR
and one CR with 11 patients with stable disease.32,33 These
interesting data represent the basis on which was designed
and has been started a phase III study (AVEREL) investigating
the efficacy of bevacizumab addition to first-line trastuzumab
and docetaxel therapy for HER2 mBC patients (n = 412).
4. Neoadjuvant and adjuvant
Ongoing trials are now evaluating the role of bevacizumab in
neoadjuvant and adjuvant setting.
In neoadjuvant setting, the phase III ongoing trial is inves-
tigating the role of adding bevacizumab to sequential combi-natorial therapy with 3 · 2 arms of treatment: docetaxel +/–
bevacizumab or docetaxel + capecitabine +/– bevacizumab or
docetaxel + gemcitabine +/– bevacizumab followed by two
arms epirubicin + cyclophosphamide (AC) +/– bevacizumab.
The primary end-point is the pathological complete response
rate (CRR), the secondary end-points are ORR, DFS and safety.
In adjuvant setting three sets of trials are ongoing for triple
negative breast cancer patients, HER2 negative and HER2 po-
sitive breast cancer patients.
In HER2 negative group two studies are investigating dif-
ferent integration schedules of bevacizumab in adjuvant ther-
apy. The E2104 study is designed to provide the ‘proof of
concept’ that bevacizumab is feasible with an anthracycline-
based therapy in adjuvant setting. E2104 is a two step phase
II trial in which node-positive patients receive chemotherapy
with doxorubicin plus cyclophosphamide followed by
paclitaxel and receive bevacizumab beginning into the
doxorubicin/cyclophosphamide phase of treatment or in the
paclitaxel phase, in this case the subsequential maintenance
with bevacizumab alone is for 22 cycles instead of 18.
The second study (E5103) is designed to primarily evaluate
the efficacy in DFS prolongation of adding bevacizumab to
sequential schedule with AC followed by paclitaxel in node-
positive or high risk node-negative, HER2-negative, resected
BC patients. Secondary end-points of this study are to com-
paring the OS of the patients treated with this regimen, to
evaluate the toxicity profile of the combination therapy and
to compare the impact of short-term (20–24 weeks) versus
long-term (50–54 weeks) administration of bevacizumab on
the DFS for this patient.
Based on the cooperative effect showed in the phase II
study performed by Pegram et al. between trastuzumab and
bevacizumab in mBC patients BETH study is evaluating the
efficacy of this combination the adjuvant setting for HER2-po-
sitive fully resected BC patients.
BEATRICE study will evaluate bevacizumab therapy in
association with standard chemotherapy regimens as adju-
vant treatment in triple negative BC patients comparing stan-
dard chemotherapy alone. The primary end-point is invasive-
DFS, and secondary end-points are OS, DFS, distant-DFS, tol-
erability and safety of the combination.
Breast cancer is often an hormone-dependent disease in
early phases. Hormones can play a role in angiogenesis, too.
In particular, regulatory regions of the VEGF gene contain ele-
ments responsive to oestrogen,34 estrogens increase VEGF lev-
els in breast cancer cell lines.35 For all these reasons many
ongoing studies are investigating the role of bevacizumab in
association with hormonal therapy. The first, GEICAM 2006-
11, is evaluating the efficacy and safety of combination of
letrozoleplusbevacizumabversus letrozole alone inpreviously
untreatedHRpositivemBCpatients suitable for a first-line hor-
monal treatment. In the second, thedouble-blindedstudyCAL-
GB40503 was evaluated the efficacy of the bevacizumab
combined with AI or tamoxifen versus AI or tamoxifen alone.
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